MANNKIND CORPORATION | 3,997 Euro | +0,040 +1,01 % | |
| WKN: A0B7MR ISIN: US56400P2011 Ticker-Symbol: NNF1 | Stuttgart | 17.05.13 | 08:06 Uhr |
Branche BiotechnologieAktienmarkt NASDAQ Biotech |
|
|
| Zeit | Aktuelle Nachrichten
Sprache: | Leser | Medien | |
|---|---|---|---|---|
| 18.05. | 1 Giant Leap for MannKind | 7 | Motley Fool | |
| 18.05. | Why MannKind's Afrezza Will Succeed Where Pfizer Failed | 14 | Seeking Alpha | |
| 15.05. | Stock Investors Bid Up Shares of MannKind, Up 8.2% | 24 | SmarTrend | |
| 13.05. | Narrower-than-Expected Loss at MannKind | 15 | Zacks | |
| 10.05. | Traders Get Bullish on Shares of MannKind, Shares Up 5.3% | 12 | SmarTrend | |
| 10.05. | MannKind 1Q loss widens on higher costs | 9 | Yahoo-USA | |
| 10.05. | MannKind Corporation's CEO Discusses Q1 2013 Results - Earnings Call Transcript | 14 | Seeking Alpha | |
| 09.05. | MannKind Q1 Loss Widens | 64 | AFX News | |
| WASHINGTON (dpa-AFX) - Drug company MannKind Corp. (MNKD) Thursday reported
first-quarter net loss to common stockholders of $41.0 million, wider than $38.2
million in the comparable quarter... Mehr lesen zu: MannKind Q1 Loss Widens | ||||
| 02.05. | Traders Get Bullish on Shares of MannKind, Shares Up 5.4% | 12 | SmarTrend | |
| 23.04. | MannKind, Ariad Pharma, Ziopharm Oncology, Galena Biopharma, and Novavax Under StockCall's Microscope | 114 | PR Newswire | |
| LONDON, April 23, 2013 /PRNewswire/ --
Following the expiration of patents on several blockbuster drugs, big pharma companies have been looking to boost their product pipeline. While in-house research... Mehr lesen zu: MannKind, Ariad Pharma, Ziopharm Oncology, Galena Biopharma, and Novavax Under StockCall's Microscope | ||||
| 17.04. | MannKind's Mysterious Lung-Safety Study Is Open But Shhh...Don't Talk About It | 24 | The Street | |
| 15.04. | MannKind's Afrezza Likely To Easily Gain Approval | 21 | Seeking Alpha | |
| 12.04. | BRIEF-MannKind shares down 7.9 pct in premarket trading | 12 | Reuters.com | |
| 12.04. | MannKind's Afrezza Likely To Fail AFFINITY 1 Phase III Trial | 28 | Seeking Alpha | |
| 10.04. | Hot Stock: MannKind, Shares Gain 9.4% | 22 | SmarTrend | |
| 05.04. | Biotech Stock Mailbag: MannKind, Ariad, Oncolytics Biotech | 27 | The Street | |
| 02.04. | Traders Get Bullish on Shares of MannKind, Shares Up 6.5% | 14 | SmarTrend | |
| 22.03. | Before the Bell Scans of MannKind, Ariad Pharma, ZIOPHARM Oncology, NPS Pharma, and Santarus | 70 | PR Newswire | |
| LONDON, March 22, 2013 /PRNewswire/ --
Biotechnology companies are expected to face significant challenges in the near future due to rising costs related to the Affordable Care Act (ACA). Increasing... Mehr lesen zu: Before the Bell Scans of MannKind, Ariad Pharma, ZIOPHARM Oncology, NPS Pharma, and Santarus | ||||
| 20.03. | MannKind: A Pure Speculative Bet | 18 | Seeking Alpha | |
| 14.03. | What's Behind MannKind's Incredible Run? | 30 | Motley Fool | |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten |
|---|---|---|---|
| VIVUS | 9,75 | -2,56 % | VIVUS (VVUS) Prices $220M Convertible Debt Offering |
| AMGEN | 82,10 | +0,91 % | XETR DIVIDEND INFORMATION - 14.05.2013 - 1 |
| AGENNIX | 0,115 | -4,17 % | DGAP-DD: Agennix AG (deutsch) |
| ONCOTHYREON | 1,525 | -6,96 % | Wedbush stuft Oncothyreon von Neutral auf Outperform. |
| QIAGEN | 14,555 | +0,38 % | Qiagen und SYGNIS Pharma schließen Lizenzvertrag |
